Integrative genomics reveal a role for MCPIP1 in adipogenesis and adipocyte metabolism.

Integrative genomics reveal a role for MCPIP1 in adipogenesis and adipocyte metabolism. Cell Mol Life Sci. 2019 Dec 31;: Authors: Losko M, Dolicka D, Pydyn N, Jankowska U, Kedracka-Krok S, Kulecka M, Paziewska A, Mikula M, Major P, Winiarski M, Budzynski A, Jura J Abstract Obesity is considered a serious chronic disease, associated with an increased risk of developing cardiovascular diseases, non-alcoholic fatty liver disease and type 2 diabetes. Monocyte chemoattractant protein-1-induced protein-1 (MCPIP1) is an RNase decreasing stability of transcripts coding for inflammation-related proteins. In addition, MCPIP1 plays an important role in the regulation of adipogenesis in vitro by reducing the expression of key transcription factors, including C/EBPβ. To elucidate the role of MCPIP1 in adipocyte biology, we performed RNA-Seq and proteome analysis in 3T3-L1 adipocytes overexpressing wild-type (WTMCPIP1) and the mutant form of MCPIP1 protein (D141NMCPIP1). Our RNA-Seq analysis followed by confirmatory Q-RT-PCR revealed that elevated MCPIP1 levels in 3T3-L1 adipocytes upregulated transcripts encoding proteins involved in signal transmission and cellular remodeling and downregulated transcripts of factors involved in metabolism. These data are consistent with our proteomic analysis, which showed that MCPIP1 expressing adipocytes exhibit upregulation of proteins involved in cellular organization and movement and decreased levels of proteins involved i...
Source: Cellular and Molecular Life Sciences : CMLS - Category: Cytology Authors: Tags: Cell Mol Life Sci Source Type: research

Related Links:

Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
AbstractTherapeutics aimed at treating non-alcoholic fatty liver disease (NAFLD) target the pathogenic process from deranged metabolism leading to steatosis to cell stress and death, leading to a cascade of inflammation and fibrosis, ultimately culminating into cirrhosis. The development of drugs for management of NAFLD has bloomed over the past decade, although at present there is no approved pharmacological agent for its management. Not all patients with the disease progress to cirrhosis and decompensation; hence, treatment specifically is provided for those with a high risk of progression such as those with biopsy-prove...
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
Authors: Valentí V, Cienfuegos JA, Becerril Mañas S, Frühbeck G Abstract Bariatric-metabolic surgery is the safest, most effective and long-lasting treatment for obesity and its associated co-morbidities, whether they be metabolic (type 2 diabetes, hyperlipidemia non-alcoholic fatty liver disease) or cardiovascular (myocardial infarction, stroke). Due to the obesity pandemic, bariatric-metabolic surgery is the second most frequent intra-abdominal procedure and the gastroenterologist and the surgeon must be aware of the physiologic changes caused by the anatomic reconfiguration following surgery. ...
Source: Revista Espanola de Enfermedades Digestivas - Category: Gastroenterology Tags: Rev Esp Enferm Dig Source Type: research
This study was designed to investigate the association of rs7903146 (C/T) polymorphism of TCF7L-2 gene with non-alcoholic fatty liver disease (NAFLD) in Asian Indians.MethodsIn this case-control study 162 non-diabetic subjects with NAFLD and 173 body mass index (BMI)-matched controls without NAFLD were recruited. Abdominal ultrasound, clinical and biochemical investigations, fasting insulin levels and value of homeostasis model assessment of insulin resistance (HOMA-IR) was measured. Single nucleotide polymorphism rs7903146 (C/T) was genotyped by polymerase chain reaction–restriction fragment length polymorphisms.Res...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Publication date: Available online 13 February 2020Source: Obesity Research &Clinical PracticeAuthor(s): Suna Kılınç, Tuna Demirbaş, Enver Atay, Ömer Ceran, Zeynep AtayAbstractContextEvidence suggests that the 1-h post-load plasma glucose (1-h PG) ≥155 mg/dL during an oral glucose tolerance test (OGTT) predicts development of type 2 diabetes (T2DM) and associated complications, among adults with normal glucose tolerance (NGT), but relevant data on children is scarce.ObjectivesTo investigate whether NGT children with obesity whose 1-h PG is ≥155 mg/dL have an increased carotid intima-media...
Source: Obesity Research and Clinical Practice - Category: Eating Disorders & Weight Management Source Type: research
Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are worldwide public health problems, affecting up to 25 –30% (NAFLD), and up to 10–15% (CKD) of the general population. Recently, it has also been established that there is a strong association between NAFLD and CKD, regardless of the presence of potential confounding diseases such as obesity, hypertension and type 2 diabetes. Since NAFLD and CKD are both common diseases that often occur alongside other metabolic conditions, such as type 2 diabetes or metabolic syndrome, elucidating the relative impact of NAFLD on the risk of incident C...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Review Source Type: research
ConclusionsUnder a combination of leflunomide and methotrexate, liver toxicity and, for the first time, thrombotic microangiopathy occurred as side effects. Non-alcoholic fatty liver disease may have predisposed for the drug-induced liver toxicity.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
This article addresses the pitfalls of the standard panel of liver function tests, discusses other non-invasive biomarkers and reviews imaging technologies which may revolutionise community-based diagnosis and stratification of chronic liver disease. PMID: 32097065 [PubMed - as supplied by publisher]
Source: British Journal of Hospital Medicine - Category: Internal Medicine Authors: Tags: Br J Hosp Med (Lond) Source Type: research
In conclusion, GCE supplementation improved glycemic parameters and obesity values and may be useful in the management of NAFLD complications. Trial registration number: IRCT201602113664N17
Source: Journal of Herbal Medicine - Category: Complementary Medicine Source Type: research
Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized public health problem, affecting up to a quarter of the world's adult population. The burden of NAFLD is influenced by the epidemics of obesity and type 2 diabetes mellitus (T2DM) and the prevalence of these conditions is not expected to decrease in the forthcoming decades. Consequently, the burden of NAFLD-related liver complications (non-alcoholic steatohepatitis [NASH], cirrhosis and hepatocellular carcinoma) and the need for life-saving liver transplantation are also expected to increase further in the near future.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Tags: Invited Review Source Type: research
More News: Alcoholism | Biology | Carbohydrates | Cardiology | Cardiovascular | Cytology | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Heart | Insulin | Liver | Liver Disease | Molecular Biology | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology